• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sernova Biotherapeutics (TSV:SVA)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Jun 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.550 (51)
Ask (Size) 1.610 (5)
Prev. Close 1.570
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late? ↗
May 26, 2022
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited... 
Via Benzinga
News headline image
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
May 06, 2022
From Sinovac Biotech Ltd.
Via Business Wire

Performance

More News

Read More
News headline image
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
April 29, 2022
From Sinovac Biotech Ltd.
Via Business Wire
News headline image
Sinovac Amends Shareholder Rights Plan
February 22, 2022
From Sinovac Biotech Ltd.
Via Business Wire
News headline image
HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗
May 05, 2022
Via InvestorPlace
News headline image
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report ↗
January 26, 2022
Via Benzinga
News headline image
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows ↗
January 24, 2022
Via Benzinga
News headline image
Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters ↗
January 03, 2022
Via Benzinga
News headline image
SINOVAC Reports Unaudited First Half of 2021 Financial Results
December 30, 2021
From Sinovac Biotech Ltd.
Via Business Wire
News headline image
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
December 09, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
SINOVAC Beijing Settled Litigation of Its Business License and Seals
December 03, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
November 09, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters ↗
September 24, 2021
Via Benzinga
News headline image
Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion ↗
September 11, 2021
Via Talk Markets
News headline image
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
September 09, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
September 08, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗
September 09, 2021
Via Benzinga
News headline image
Inovio To Start Global Late-Stage COVID-19 Vaccine Trial ↗
August 26, 2021
Via Benzinga
News headline image
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
August 10, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine ↗
July 20, 2021
Via Benzinga
News headline image
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
July 19, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot ↗
July 16, 2021
Via Benzinga
News headline image
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
July 12, 2021
From SINOVAC Biotech Ltd.
Via Business Wire
News headline image
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
June 30, 2021
From Sinovac Biotech Ltd.
Via Business Wire
News headline image
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use
June 02, 2021
From SINOVAC Biotech Ltd.
Via Business Wire

Frequently Asked Questions

Is Sernova Biotherapeutics publicly traded?
Yes, Sernova Biotherapeutics is publicly traded.
What exchange does Sernova Biotherapeutics trade on?
Sernova Biotherapeutics trades on the Toronto Venture Stock Exchange
What is the ticker symbol for Sernova Biotherapeutics?
The ticker symbol for Sernova Biotherapeutics is SVA on the Toronto Venture Stock Exchange
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap